These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids
Larson, Glucose levels and risk of dementia, N
Each of these has been linked to specific health benefits, and theyre all often used as natural treatments for conditions like cold sores, depression or insomnia
Eur Rev Med Pharm Sci
Nat Commun 7:12394 Jin H, Wan C, Zou Z, Zhao G, Zhang L, Geng Y, Chen T, Huang A, Jiang F et al (2018) Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel